DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2-Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Positive Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the HER2-Positive Breast Cancer Pipeline Report
- DelveInsight’s HER2-Positive Breast Cancer pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for HER2-Positive Breast Cancer treatment.
- The leading companies working in the HER2-Positive Breast Cancer Market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co. Ltd, Jiangsu HengRui Medicine Co. Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics Inc., Horizon Therapeutics, and others.
- Promising HER2-Positive Breast Cancer Pipeline Therapies in the various stages of development include TUKYSA®, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, SYSA1901, Docetaxel, and others.
- December 2023: Seagen Inc. announced a study of Phase 3 clinical trials for Tucatinib and Trastuzumab. This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
- November 2023: University of California, San Francisco announced a study of Phase 2 clinical trials for Neratinib and Loperamide. This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system.
Request a sample and discover the recent advances in HER2-Positive Breast Cancer Treatment Drugs @ HER2-Positive Breast Cancer Pipeline Outlook Report
In the HER2-Positive Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Positive Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
HER2-Positive Breast Cancer Overview
Breast cancer is not a single disease but a group of diseases. Scientists discovered human epidermal growth factor receptor 2 (HER2)-positive breast cancer when searching for genes that cause cancer. On the most basic level, cancer is the result of normal cells growing unchecked, an observation that led researchers to speculate that specific genes or gene mutations enable this to occur.
Find out more about HER2-Positive Breast Cancer Therapeutics Assessment @ HER2-Positive Breast Cancer Preclinical and Discovery Stage Products
HER2-Positive Breast Cancer Emerging Drugs Profile
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- HLX11: Shanghai Henlius Biotech
- MCLA-128: Merus N.V.
- DX126 262: Hangzhou DAC Biotech
HER2-Positive Breast Cancer Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for HER2 Positive Breast Cancer. The HER2-Positive Breast Cancer companies which have their HER2 Positive Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.
DelveInsight’s HER2-Positive Breast Cancer pipeline report covers around 65+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
HER2 Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
HER2-Positive Breast Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging HER2-Positive Breast Cancer Pipeline Therapies @ HER2-Positive Breast Cancer Clinical Trials Assessment
Scope of the HER2-Positive Breast Cancer Pipeline Report
- Coverage- Global
- HER2-Positive Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- HER2-Positive Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- HER2-Positive Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co. Ltd, Jiangsu HengRui Medicine Co. Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics Inc., Horizon Therapeutics, and others.
- HER2-Positive Breast Cancer Pipeline Therapies- TUKYSA®, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, SYSA1901, Docetaxel, and others.
Dive deep into rich insights for new drugs for HER2-Positive Breast Cancer Treatment, Visit @ HER2-Positive Breast Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- HER2 Positive Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- HER2 Positive Breast Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- Drug profiles in the detailed report…..
- Mid-Stage Products (Phase II)
- MCLA-128: Merus N.V.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DX126 262: Hangzhou DAC Biotech
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- ES2B C001: ExpreS2ion Biotechnologies
- Drug profiles in the detailed report…..
- Inactive Products
- HER2 Positive Breast Cancer Key Companies
- HER2 Positive Breast Cancer Key Products
- HER2 Positive Breast Cancer- Unmet Needs
- HER2 Positive Breast Cancer- Market Drivers and Barriers
- HER2 Positive Breast Cancer- Future Perspectives and Conclusion
- HER2 Positive Breast Cancer Analyst Views
- HER2 Positive Breast Cancer Key Companies
- Appendix
For further information on the HER2-Positive Breast Cancer Pipeline therapeutics, reach out to HER2-Positive Breast Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market